Bristol Myers Squibb receives European Commission Approval for Luspatercept (Reblozyl (R)) for the Treatment of adult Patients with transfusion-dependent Anemia associated with MDS Disease or Beta Thalassemia-MedSci.cn

Bristol Myers Squibb receives European Commission Approval for Luspatercept (Reblozyl (R)) for the Treatment of adult Patients with transfusion-dependent Anemia associated with MDS Disease or Beta Thalassemia

[Anonymous]

TRANSFUSION MEDICINE AND HEMOTHERAPY, 2020; 47 (4): 344

科室
- - 订阅+
  - 更多科室
工具
服务